Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "peptides"

83 News Found

Beiersdorf and Macro Biologics announce partnership to develop antimicrobial peptides
News | September 06, 2024

Beiersdorf and Macro Biologics announce partnership to develop antimicrobial peptides

Multi-year collaboration focuses on development of biodegradable antimicrobial peptides with broad application possibilities in the areas of skin care and healthcare


Briefs: IOL Chemicals and Pharmaceuticals and Auro Peptides
News | February 20, 2024

Briefs: IOL Chemicals and Pharmaceuticals and Auro Peptides

IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China


Laurus Labs Q4 profit rises to Rs. 279 crore, FY26 revenue up 23%
News | May 06, 2026

Laurus Labs Q4 profit rises to Rs. 279 crore, FY26 revenue up 23%

The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms


Syngene reports FY26 revenue of Rs 3,739 Cr, up 3%; Q4 revenue at Rs 1,037 Cr
News | April 30, 2026

Syngene reports FY26 revenue of Rs 3,739 Cr, up 3%; Q4 revenue at Rs 1,037 Cr

Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities


Granules India  Q4FY26 revenue jumps 23% to Rs 14,706 million; FY26 revenue at Rs 53,656 million
News | April 29, 2026

Granules India Q4FY26 revenue jumps 23% to Rs 14,706 million; FY26 revenue at Rs 53,656 million

The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform


Aurigene bets big on CRDMO expansion with $100 million outlay
News | April 28, 2026

Aurigene bets big on CRDMO expansion with $100 million outlay

Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities


Japanese pharma firms turn to CDMOs early as peptide complexity rises
News | April 23, 2026

Japanese pharma firms turn to CDMOs early as peptide complexity rises

Neuland Laboratories reported an uptick in peptide-related engagements from Japanese companies, particularly at the preclinical and early clinical stages


Strengthening India’s pharma brand through compliance-first manufacturing: Vijay Kumar Aggarwal, MD, Medicef Pharma
Opinion | April 21, 2026

Strengthening India’s pharma brand through compliance-first manufacturing: Vijay Kumar Aggarwal, MD, Medicef Pharma

By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership


MSN Laboratories launches SEMABEST, India-made semaglutide pen at nearly 50% lower price
Drug Approval | April 15, 2026

MSN Laboratories launches SEMABEST, India-made semaglutide pen at nearly 50% lower price

CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing


Saharsh Davuluri takes over as CEO & MD of Neuland  Laboratories
Appointment | April 02, 2026

Saharsh Davuluri takes over as CEO & MD of Neuland Laboratories

18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist